COVID-19：ブルガリアでイベルメクチンの治験良好：Economic.BG（動画）：
Bulgarian Randomized､Double-Blind､Placebo Ivermectin Study Shows Positive:
保加利亚随机，双盲，安慰剂对照伊维菌素研究显示抗COVID-19的阳性结果
ブルガリアのイベルメクチン治験：
無作為化・二重盲検・プラセボ対照の、イベルメクチン治験が行われました。
ブルガリアのメディアアウトレットEconomic.BGからの報告です。
研究（EUDRACT2020-002091-12）
- PCR検査が陽性で、
- 治療開始の7日前までに症状が現れた、
- 個人を対象に募集・登録しました。
患者に投与：
1日あたり400μg/ kgのイベルメクチンの用量で、薬剤投与を実施。
3日間連続して、プラセボも投与されました。
100人の患者：
Huvemex群とプラセボ群の両方を用いたこのランダム化試験を実施。
Results
As reported in Economic.BG, the results reveal that
the study drug accelerated the clearance of the virus (as evidenced by reading of RT-PCR tests) by day 3 and 4 post treatment start date.
The investigators also
observed marked improvement in patient clinical condition for those in the study drug arm based on the WHO 9- category ordinal scale).As compared to placebo,
the participants receiving the ivermectin based drug fared better, statistically than those in the placebo group.Interestingly,
the study sponsors
observed that the ivermectin-based drug appeared associated with the suppression and normalization of important inflammation biomarkers, considered by many scientists as an important indicator of pathological processes associated with COVID-19 disease progression—including D-Dimer and C-Reactive Protein (CRP).The sponsors
shared with Bulgarian press that the study drug on average started to make its positive impact felt.